AbbVie Inc (ABBV)vsAmgen Inc (AMGN)
ABBV
AbbVie Inc
$208.34
-1.01%
HEALTHCARE · Cap: $391.56B
AMGN
Amgen Inc
$351.48
-0.44%
HEALTHCARE · Cap: $197.43B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 66% more annual revenue ($61.16B vs $36.75B). AMGN leads profitability with a 21.0% profit margin vs 6.9%. ABBV appears more attractively valued with a PEG of 0.53. AMGN earns a higher WallStSmart Score of 70/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
AMGN
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1179.3%
Fair Value
$16.12
Current Price
$208.34
$192.22 premium
Margin of Safety
+47.5%
Fair Value
$666.90
Current Price
$351.48
$315.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 4.9B in free cash flow
Every $100 of equity generates 106 in profit
Strong operational efficiency at 30.5%
Earnings expanding 112.1% YoY
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Trading at 21.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 93.4x leaves little room for execution misses.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
ABBV profiles as a value stock while AMGN is a mature play — different risk/reward profiles.
AMGN carries more volatility with a beta of 0.42 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
AMGN scores higher overall (70/100 vs 63/100), backed by strong 21.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?